Ucb Pharma Gmbh

Rheinische Friedrich-wilhelms-universitat Bonn

Joerg Hockemeyer

Cécile Pegurier

Ali El-Tayeb

Christa E Mueller

Marie Ledecq

Laurent Provins

Sanjay Bhattarai

Vigneshwaran Namasivayam

Mario Funke

Lukas Schwach

Sabrina Gollos

Michael Louis Robert Deligny

Joël Mercier

Nader M Boshta

Anaïs Barré

Daniel Von Laufenberg

Larurent Provins

Silvia Lovera

Mahmoud Rashed

Alvaro Cardenas

Nader Boshta

Yong-Qiang Zhang

Christa MUeller

Nikolay Tzvetkov

Joachim Burbiel

Disclosed are N-(phenyl)-1H-indole-3-sulfonanmide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis.

N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides

The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.

Pyridinyl and pyrazinyl-(asa)indolsulfonamides

Growing community of inventors

Bonn, Germany

Joerg Hockemeyer